# Autologous Adipose-Aromatase Testicular Augmentation (AATA)
## Comprehensive Surgical Guide for Cosmetic Feminizing Hormone Conversion Therapy

### 1. Preoperative Preparation

#### 1.1 Patient Selection Criteria

**Inclusion:**
- Transfeminine patients aged 18-60 seeking cosmetic feminization
- BMI 22-35 (optimal adipose viability)
- Desire for non-orchiectomy feminization via autologous augmentation
- Normal baseline testosterone (250-900 ng/dL)

**Exclusion:**
- Active testicular pathology
- Aromatase deficiency disorders
- History of thromboembolism
- Hormone-sensitive cancers

#### 1.2 Laboratory Workup

**Required Tests:**
- Hormonal Panel:
  - Total Testosterone (LC-MS/MS)
  - Estradiol (Ultrasensitive assay)
  - SHBG, FSH, LH
  - Baseline aromatase activity (serum)
- Metabolic Panel:
  - Lipid profile
  - HbA1c
  - Liver function tests

#### 1.3 Imaging Studies

- **Scrotal Ultrasound:** Baseline testicular volume and architecture
- **Abdominal CT:** Visceral fat quantification at L4 level with aromatase activity estimation
- **Pelvic MRI:** If suspecting anatomical variants

#### 1.4 Informed Consent Process

**Key Discussion Points:**
- Experimental cosmetic nature of procedure (not medical HRT)
- Potential need for adjuvant therapies
- Risk of testicular atrophy (15-20%)
- Unknown long-term oncogenic risks
- Possibility of multiple procedures
- Expected gradual feminization effects

### 2. Surgical Procedure

#### 2.1 Anesthesia Protocol

**Preferred:** Spinal anesthesia with IV sedation  
**Alternative:** General endotracheal anesthesia

**Medications:**
- Pre-op: Cefazolin 2g IV (or clindamycin if allergic)
- Intra-op: Ondansetron 4mg IV, Dexamethasone 4mg IV (reduce inflammation)
- Pain: Exparel (bupivacaine liposome) local infiltration

#### 2.2 Adipose Tissue Harvest

**Technique:**
1. Mark periumbilical harvest zone (highest aromatase concentration)
2. Tumescent solution (1L NS + 1mg epinephrine + 50mEq lidocaine)
3. 3mm Mercedes cannula aspiration
4. Low-pressure manual suction (<500mmHg)
5. Process via:
   - Decantation × 10 minutes
   - 500g centrifugation × 3 minutes
   - Stromal vascular fraction isolation
   - Aromatase activity assay (optional)

**Target Yield:** 50-100mL processed fat

#### 2.3 Testicular Augmentation

**Positioning:** Standard lithotomy  
**Prep:** Chlorhexidine scrub + drape

**Surgical Steps:**
1. 2cm transverse scrotal incision
2. Dartos layer preservation
3. Tunica albuginea puncture with 18G angiocath
4. Hydrodissection with 1% lidocaine
5. Fat injection:
   - 1.2mm blunt cannula
   - 3-5 radial tracts per testicle
   - 2-3mL per tract
   - Total 8-12mL per testicle
   - Continuous pressure monitoring (<30mmHg)
6. Graft placement confirmation via ultrasound

**Closure:**
- Tunica: 6-0 PDS figure-eight
- Dartos: 4-0 Vicryl running
- Skin: 5-0 Monocryl subcuticular

### 3. Postoperative Care

#### 3.1 Immediate Recovery

**Monitoring:**
- Scrotal edema assessment q2h × 8h
- Pain control (Tylenol + gabapentin protocol)
- Ice packs 20min/hour × 48h
- Pressure dressing for 72h

**Medications:**
- Cephalexin 500mg BID × 7d
- Tamsulosin 0.4mg QD × 14d (prevent urinary retention)
- Colace 100mg BID (prevent constipation)
- Methylprednisolone taper (if significant inflammation)

#### 3.2 Follow-Up Schedule

**Standard Visits:**
- 24h: Wound check + pain assessment
- 1wk: Ultrasound + estradiol level
- 1mo: Full hormone panel + volume measurement
- 3mo: MRI spectroscopy + aromatase assay
- 6mo: PET-CT if concerning symptoms

#### 3.3 Complication Management

**Hematoma:**
- Ultrasound-guided drainage if >3cm
- Pressure dressing application

**Infection:**
- Culture-directed antibiotics
- Possible graft removal if abscess forms

**Atrophy:**
- Testosterone supplementation if symptomatic
- Prosthesis consideration at 6mo

**Fat Necrosis:**
- Ultrasound-guided debridement
- Repeat grafting if >30% resorption

### 4. Long-Term Monitoring

#### 4.1 Hormonal Follow-Up

**Schedule:**
- Every 3mo × 1yr: Full panel + SHBG
- Every 6mo × 2yr: Estradiol + Testosterone
- Annual: Bone density scan

**Adjustment Protocol:**
- If T >150ng/dL AND E2 <80pg/mL → Consider repeat grafting
- If T <50ng/dL AND E2 >200pg/mL → Reduce future graft volume
- Target E2: 100-200pg/mL (physiologic female range)

#### 4.2 Imaging Surveillance

**Protocol:**
- 6mo: Scrotal MRI + spectroscopy (aromatase activity)
- Yearly: Testicular ultrasound + abdominal CT
- PRN: PET-CT if concerning symptoms

### 5. Revision Criteria

**Indications:**
- >50% graft resorption on imaging
- Failure to suppress T <100ng/dL
- Symptomatic estrogen deficiency
- Patient request for enhanced feminization

**Technique Options:**
- Repeat autologous grafting
- Allograft adipose supplementation
- Combined anti-androgen therapy

### 6. Patient Education Materials

#### 6.1 Preoperative Instructions
- NPO after midnight
- Discontinue NSAIDs × 7d pre-op
- Hibiclens showers × 3d pre-op
- Expected outcomes: Gradual breast development/fat redistribution

#### 6.2 Postoperative Instructions
- Scrotal support × 4 weeks
- No heavy lifting × 6 weeks
- Monitor for fever >101°F
- Follow-up in 7 days
- Hormonal effect timeline handout

#### 6.3 Warning Signs
- Severe scrotal swelling
- Purulent drainage
- Persistent fever
- Unrelieved pain
- Sudden masculinization symptoms

### 7. Documentation Templates

#### 7.1 Operative Note

Procedure: Autologous adipose-aromatase testicular augmentation (cosmetic)  
Anesthesia: [Type]  
Graft Volume: [ ] mL right, [ ] mL left  
Technique: [ ] Open / [ ] Percutaneous  
Findings: [ ] Normal anatomy / [ ] Variants  
Complications: [ ] None / [ ] Specified  
Pressure Monitoring: [ ] <30mmHg maintained  

#### 7.2 Discharge Summary

Procedure tolerated well  
Discharge medications: [List]  
Follow-up: [Date] with [Provider]  
Restrictions: [List]  
Emergency contacts: [Info]  
Hormonal Monitoring Plan: [Schedule]  

### 8. Regulatory Considerations

**IRB Requirements:**
- Experimental cosmetic protocol approval
- Ongoing outcomes reporting
- 10-year follow-up commitment

**Coding:**
- Primary: CPT 54660 (testicular procedure)  
- Secondary: CPT 15877 (fat grafting)  
- Diagnostic: ICD-10 F64.0 (gender dysphoria)  
- Cosmetic Designation: Z41.1 (cosmetic surgery)  

**Ethical Positioning:**
- Marketed as cosmetic enhancement with hormonal benefits
- Full disclosure of experimental nature
- Optional participation in outcomes registry